Page 6 - Cipla

Stocks to Watch: Torrent Pharma, Cipla, TVS Supply Chain, Titan, AdaniTotal

Stocks to Watch on August 23, 2023: Torrent Pharma has joined the race to buy out Cipla's promoter stake held by the Hamied family, reported The Economic Times

Sensex falls 388 pts, Nifty holds 19,350 amid weak global cues; PSBs outrun

Closing Bell on August 17, 2023: On the upside, only the Nifty PSU Bank index (up 1.5 per cent) outperformed the markets

Stocks to Watch today, Aug 17: Auto, M&M, Railway, IRFC, Cipla, Nava, SAIL

Stocks to watch on August 17, 2023: Balrampur Chini, Delta Corp, GNFC, Indiabulls Housing Finance, India Cements, SAIL and Zee among 11 stocks in F&O ban on Thursday.

Cipla's impending 'takeover' by Blackstone should sadden all of us: Jairam

Senior Congress leader Jairam Ramesh on Friday said Indian pharmaceutical company Cipla is an integral part of the country's political, economic and social history and its "impending takeover" by Blackstone should sadden everyone. The Congress general secretary shared a media report on Twitter which claimed that Blackstone, the world's largest private equity fund, is set to submit a non-binding bid as early as next week to acquire the entire 33.47 per cent promoter stake in Cipla. "It was painful to learn that Blackstone, the world's largest private equity fund, is negotiating to acquire the entire 33.47% promoter stake in Cipla, India's oldest pharmaceutical company," Ramesh, who is the chairman of Parliamentary standing committee on science and technology, environment and climate change, said. Cipla was established in 1935 by Khwaja Abdul Hamied, who was profoundly impacted by Mahatma Gandhi, Jawaharlal Nehru, Sardar Patel and Maulana Abul Kalam Azad. He also played an important

Cipla hits new high; up 6% on promoter stake sale buzz, strong Q1 results

With regards to the promoters stake sale buzz, the company said it will make appropriate disclosure in compliance with the Listing Regulations as and when any such requirement arises.

Stocks to Watch: Bharti Airtel, Adani Ent, Cipla, RailTel, Indian Hotels

Stocks to Watch on July 28, 2023: Despite a 10 per cent increase in revenue, telecom provider Airtel Africa announced a net loss of $151 million in the first quarter (April-June) of FY24 on Thursday

Blackstone, Baring in race to acquire up to 20% stake in pharma firm Cipla

Cipla shares closed 9.6 per cent up on Thursday to Rs. 1,175

Never again will India be starved of essential drugs, says Cipla founder

As of July 27, Cipla's market cap stands at Rs 94572 crore

Top shareholders of drugmaker Cipla looking to sell stake: Report

The company has hired an investment bank to advise on the deal, the report said

Cipla surges 9% on strong Q1 results, raises FY24 margin guidance

For FY24, Cipla raised its EBITDA margin guidance to 23 per cent from 22 per cent earlier.

Cipla Q1FY24 result: Net profit at Rs 895.02 crore; revenue up by 12.2%

The company's One-India business grew by 12 per cent YoY. Their US business reported highest-ever revenue of $222 million and 43 per cent YoY growth

Cipla Q1 preview: India biz may push profit over 50% QoQ; US sales to drag

Cipla Q1 preview: The company's domestic business can grow 15 per cent quarter-on-quarter (QoQ), while US business could contract by up to 4 per cent QoQ to $195 million

Cipla's US unit recalls 6 batches of bronchospasm inhaler over defect

'The company is initiating a recall in the US due to a market complaint for one single inhaler, where leakage was observed through the inhaler valve,' the pharmaceutical company said in a statement

Delhi HC restrains Cipla from using Gluco-C or Gluco-D trademarks

Zydus argued that Cipla started branding its Glucose product under Gluco C ++ and Gluco D ++, in order to create confusion in the minds of customers

Stocks to watch: Coal India, Mankind Pharma, EID Parry, India Pesticides

Stocks to watch on June 1, 2023: From Coal India to Mankind Pharma, here are top stocks to watch in Thursday's trading session

Cipla's Q4 net profit up 45% at Rs 526 cr on account of robust sales

Drug major Cipla on Friday said its consolidated net profit increased by 45 per cent to Rs 526 crore for the fourth quarter ended March 31, 2023, driven by robust sales across the domestic business and US market. The Mumbai-based company had reported a net profit of Rs 362 crore for the January-March quarter of 2021-22 fiscal. Total revenue from operations rose to Rs 5,739 crore for the fourth quarter as compared with Rs 5,260 crore in the year-ago period, Cipla said in a regulatory filing. For the year ended March 31, 2023, the drug maker reported a consolidated net profit of Rs 2,802 crore as against Rs 2,517 crore in FY22. Total revenue rose to Rs 22,753 crore last fiscal as against Rs 21,763 crore in 2021-22 fiscal. "In FY23, we recorded the highest ever revenue with EBITDA crossing Rs 5,000 crore for the first time. Our One-India business continued the double-digit trajectory growing at 13 per cent ex-Covid during the year led by branded prescription and sustained growth acros

Results preview: India business to put a spring in pharma's step

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels

Stocks to watch: JSW Steel, Cipla, Zydus Life, Kaveri Seed, Kalpataru Power

Stocks to watch today: From Cipla to Zydus Lifesciences, here are top stocks to watch in Tuesday's trading session

Cipla inks licensing pact with Novartis to manufacture, mkt diabetes drug

Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026. The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing. "This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added. The agreement is subject to satisfaction of certain conditions precedent, the drug firm said. Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category, the drug firm stated. On Monday, shares of Cipla ended 1.02 per cent up at Rs 901.85 apiece on the BSE.

Sensex falls for 5th straight day, ends 344 pts down; Nifty breaks 17,000

CLOSING BELL: The Nifty 50 ended below the 17,000-mark for the first time since October 11, 2022. The NSE benchmark has now shed 630 points in the last five trading sessions.